A B Robertone
Overview
Explore the profile of A B Robertone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
7
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taylor C, Salmon S, Satterlee W, Robertone A, McCloskey T, Holdsworth M, et al.
Invest New Drugs
. 1990 Jan;
8 Suppl 1:S51-7.
PMID: 2380017
The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days. Forty-two patients were treated in this phase...
2.
Durie B, Clouse L, Braich T, Grimm M, Robertone A
Semin Oncol
. 1986 Sep;
13(3 Suppl 2):84-8.
PMID: 3764444
Since interferon alfa-2b (Intron A) is useful as a single agent, it is important to determine if interferon can be combined with standard chemotherapy to improve both response and survival...
3.
Takasugi B, Jones S, Robertone A
Cancer Treat Rep
. 1984 Nov;
68(11):1399-401.
PMID: 6498855
Vinzolidine, a semisynthetic vinblastine derivative, was tested in an oral formulation in 21 heavily pretreated patients with lymphoma. Partial remissions were seen in four patients with Hodgkin's disease (50%) and...
4.
Takasugi B, Robertone A, Salmon S, Jones S, Alberts D
Invest New Drugs
. 1984 Jan;
2(4):387-90.
PMID: 6096287
This Phase I-II trial evaluated vinzolidine (VZL), a semisynthetic vinblastine derivative administered on a five-day oral schedule every 21 days, with 60% of the total dose on day 1 followed...